Atogepant vs. rimegepant cost per treatment responder analysis for the preventive treatment of episodic migraine

被引：0
|
作者：
Ailani, J. [1 ]
Gandhi, P. [2 ]
Lalla, A. [3 ]
Singh, R. B. Halker [4 ]
McAllister, P. [5 ]
Smith, J. H. [6 ]
Dabruzzo, B. [2 ]
Chalermpalanupap, N. [2 ]
Nahas, S. J. [7 ]
机构：
[1] MedStar Georgetown Univ Hosp, Washington, DC USA
[2] AbbVie, Madison, NJ USA
[3] AbbVie, Irvine, CA USA
[4] Mayo Clin, Scottsdale, AZ USA
[5] New England Inst Neurol & Headache, Stamford, CT USA
[6] AbbVie, N Chicago, IL USA
[7] Thomas Jefferson Univ, Dept Neurol, Jefferson Headache Ctr, Philadelphia, PA 19107 USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2024年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P051
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Fremanezumab as a preventive treatment for episodic and chronic migraine
    Bigal, Marcelo E.
    Walter, Sarah
    Rapoport, Alan M.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (08) : 719 - 728
  • [32] SECUKINUMAB VS. ADALIMUMAB AND INFLIXIMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS AT 52 WEEKS FROM A GREEK PERSPECTIVE
    Daoussis, D.
    Theofanidis, N.
    Kalogeropoulou, M.
    VALUE IN HEALTH, 2019, 22 : S420 - S421
  • [33] SECUKINUMAB VS. ADALIMUMAB FOR THE TREATMENT OF PS ORIATIC ARTHRITIS: A COST PER RESPONDER ANALYSIS AT 48 WEEKS FROM AN ARGENTINIAN PERSPECTIVE
    Barbeau, M.
    Bianculli, P. M.
    Nikoglou, E.
    Gunda, P.
    Jugl, S. M.
    MacPherson, A.
    VALUE IN HEALTH, 2017, 20 (09) : A534 - A535
  • [34] A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective
    Kim, Dam
    Kim, Hyojin
    Cho, SeongHa
    Park, Min-Chan
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2019, 22 (09) : 1630 - 1637
  • [35] MSQ Utility Mapping of Rimegepant by Change in Monthly Migraine Days for Preventive Treatment of Migraine
    Johnston, Karissa
    L'Italien, Gilbert
    Popoff, Evan
    Powell, Lauren
    O'Sullivan, Fiona
    Harris, Linda
    Croop, Robert
    Coric, Vlad
    Lipton, Richard B.
    NEUROLOGY, 2022, 98 (18)
  • [36] Monoclonal antibodies for preventive treatment of episodic and chronic migraine
    Bigal, M.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 357 : E459 - E460
  • [37] Daily atogepant provides a rapid onset and sustained benefit in the preventive treatment of migraine
    Schwedt, T. J.
    Lipton, R. B.
    Ailani, J.
    Silberstein, S. D.
    Tassorelli, C.
    Guo, H.
    Lu, K.
    Dabruzzo, B.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    HEADACHE, 2021, 61 : 119 - 119
  • [38] Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine (vol 37, pg 255, 2023)
    Blair, Hannah A. A.
    CNS DRUGS, 2023, 37 (07) : 661 - 661
  • [39] Atogepant for the Preventive Treatment of Chronic Migraine in Europe: Results From the PROGRESS Study
    Goadsby, P.
    Pozo-Rosich, P.
    Ashina, M.
    Reuter, U.
    Moisset, X.
    Trugman, J.
    Ha, H.
    Schwefel, B.
    Nagy, K.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [40] Daily Atogepant Provides a Rapid Onset and Sustained Benefit in the Preventive Treatment of Migraine
    Schwedt, T. J.
    Lipton, R. B.
    Ailani, J.
    Silberstein, S. D.
    Tassorelli, C.
    Guo, H.
    Lu, K.
    Dabruzzo, B.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 107 - 107
12345